Evidence map›Paper›PMID 35289971›Full record

ArticleCell proliferation2022

Selection of O-negative induced pluripotent stem cell clones for high-density red blood cell production in a scalable perfusion bioreactor system.

SuE Yu, Svetlan Vassilev, Zhong Ri Lim, Jaichandran Sivalingam, Alan Tin Lun Lam, Valerie Ho, Laurent Renia, Benoit Malleret, Shaul Reuveny, Steve Kah Weng Oh

Open access · goldAbstract read
In one paragraph

Article in Cell proliferation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

SuE YuStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Svetlan VassilevStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.ORCID https://orcid.org/0000-0001-8639-9312
Zhong Ri LimStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Jaichandran SivalingamStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Alan Tin Lun LamStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.ORCID https://orcid.org/0000-0001-6831-9518
Valerie HoStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Laurent ReniaSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Benoit MalleretSingapore Immunology Network, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Shaul ReuvenyStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Steve Kah Weng OhStem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Republic of Singapore.
Agency for Science, Technology and Research · SG

Funding

Agency for Science, Technology and Research 1331AFG075
6 · The paper itself

Abstract

objectivesLarge-scale generation of universal red blood cells (RBCs) from O-negative (O-ve) human induced pluripotent stem cells (hiPSCs) holds the potential to alleviate worldwide shortages of blood and provide a safe and secure year-round supply. Mature RBCs and reticulocytes, the immature counterparts of RBCs generated during erythropoiesis, could also find important applications in research, for example in malaria parasite infection studies. However, one major challenge is the lack of a high-density culture platform for large-scale generation of RBCs in vitro. MATERIALS AND

methodsWe generated 10 O-ve hiPSC clones and evaluated their potential for mesoderm formation and erythroid differentiation. We then used a perfusion bioreactor system to perform studies with high-density cultures of erythroblasts in vitro.

resultsBased on their tri-lineage (and specifically mesoderm) differentiation potential, we isolated six hiPSC clones capable of producing functional erythroblasts. Using the best performing clone, we demonstrated the small-scale generation of high-density cultures of erythroblasts in a perfusion bioreactor system. After process optimization, we were able to achieve a peak cell density of 34.7 million cells/ml with 92.2% viability in the stirred bioreactor. The cells expressed high levels of erythroblast markers, showed oxygen carrying capacity, and were able to undergo enucleation.

conclusionsThis study demonstrated a scalable platform for the production of functional RBCs from hiPSCs. The perfusion culture platform we describe here could pave the way for large volume-controlled bioreactor culture for the industrial generation of high cell density erythroblasts and RBCs.

Indexed as

Induced Pluripotent Stem CellsBioreactorsCell DifferentiationClone CellsErythrocytesErythropoiesisHumansPerfusion

Identifiers

PMID35289971
PMCPMC9357363
OpenAlexW4220768248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.